Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price114.03 USD
Fair value130.43
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Accumulation114.03+0.0% to today ✓
2026-07-02Read Markup82.91+37.5% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Corcept Therapeutics Incorporated holds its Accumulation at $114.03. Consolidating, no directional conviction, held for 128 days.
As held on the ledger · 2026-10-01
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 128 days
Price at the screen
$114.03
Valuation
253.39 trailing · 25.90 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.45
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.73%
Below 33%
Interest-bearing debt is just 0.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
19.16%
Below 33%
Cash held in interest-bearing accounts and securities is 19.2% of assets, under the one-third limit.
Pass
Receivables
21.55%
Below 49%
Money owed to the company is 21.5% of assets, under the 49% limit.
Pass
Revenue purity
2.85%
Below 5%
Only 2.8% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Corcept Therapeutics clears all five screens. Its business is in a permissible area, its debt is near-nil, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-01 screen. The gold marker is the market price at the same screen. A 14.4% margin of safety to the base estimate.
Third-party analyst targets: 5 covering, consensus Buy. The average target sits +44% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech Drugmaker Priced Above Its Worth
Picture a company selling one key pill for rare hormone disorders while promising new treatments down the line. Corcept sits in that spot, yet its numbers tell a tighter story than the hype suggests. Revenue edges up just 5 percent, returns on equity sit at 7 percent, and profit margins barely clear 6 percent, all while shares trade at 28 times forward earnings.
We pass because the price sits 9 percent above our fair value with no margin of safety and an opportunity rating of none. Analyst targets hover near 95 dollars, but that optimism rests on thin growth and an unknown competitive edge rather than proven scale or durable cash flow.
Risks include heavy reliance on a single product, slow revenue momentum, and the usual biotech hurdles around trials and regulation. The ethical screen clears, yet the valuation leaves little room for error. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CORT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it strong buy, with a mean price target of $88. Insiders have been net sellers over the past quarter.
2026-08-25Markup$107.95+19.3%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 19.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it strong buy, with a mean price target of $88.
2026-07-25Markup$90.52+9.2%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it strong buy, with a mean price target of $88.
2026-07-18Markup$82.91+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (5 analysts) rates it strong buy, with a mean price target of $88.
2026-07-03Markup$82.91+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$82.91Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
